Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors

Journal of Medicinal Chemistry
2015.0

Abstract

Dengue virus is an increasingly global pathogen. One of the promising targets for antiviral drug discovery against dengue and related flaviviruses such as West Nile virus is the viral serine protease NS2B-NS3. We here report the synthesis and in vitro characterization of potent peptidic inhibitors of dengue virus protease that incorporate phenylalanine and phenylglycine derivatives as arginine-mimicking groups with modulated basicity. The most promising compounds were (4-amidino)-L-phenylalanine-containing inhibitors, which reached nanomolar affinities against dengue virus protease. The type and position of the substituents on the phenylglycine and phenylalanine side chains has a significant effect on the inhibitory activity against dengue virus protease and selectivity against other proteases. In addition, the non-natural, basic amino acids described here may have relevance for the development of other peptidic and peptidomimetic drugs such as inhibitors of the blood clotting cascade.

Knowledge Graph

Similar Paper

Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors
Journal of Medicinal Chemistry 2015.0
A New Class of Dengue and West Nile Virus Protease Inhibitors with Submicromolar Activity in Reporter Gene DENV-2 Protease and Viral Replication Assays
Journal of Medicinal Chemistry 2020.0
Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture
Journal of Medicinal Chemistry 2021.0
Progress and prospects on DENV protease inhibitors
European Journal of Medicinal Chemistry 2016.0
Discovery of antiviral molecules for dengue: In silico search and biological evaluation
European Journal of Medicinal Chemistry 2016.0
Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture
Bioorganic & Medicinal Chemistry 2011.0
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents
Bioorganic & Medicinal Chemistry 2010.0
A short survey of dengue protease inhibitor development in the past 6 years (2015–2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases
Bioorganic & Medicinal Chemistry 2021.0
Preparation of l-proline based aeruginosin 298-A analogs: Optimization of the P1-moiety
Bioorganic & Medicinal Chemistry Letters 2009.0
Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2–P1′ Region
ACS Medicinal Chemistry Letters 2014.0